Clinical experience with abciximab during coronary revascularisation: an overview

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Pharmacology

Background:

• Percutaneous transluminal coronary angioplasty (PTCA) carries a risk of ischaemic complications.
• Platelets play a key role in arterial thrombosis after coronary intervention.
• Platelet glycoprotein (GP) IIb/IIIa receptor inhibition targets the final common pathway of platelet aggregation.

Purpose of the Study:

• To evaluate the efficacy and safety of abciximab (c7E3 Fab) in reducing ischaemic complications during coronary angioplasty.
• To assess the impact of GP IIb/IIIa receptor inhibition on acute ischaemic events and restenosis following PTCA.

Main Methods:

• Phase III clinical trials (EPIC, EPILOG, CAPTURE) involving 6156 patients undergoing coronary angioplasty.
• Administration of abciximab, a chimaeric antibody fragment targeting the GP IIb/IIIa receptor.
• Comparison of abciximab treatment arms with placebo or standard care, with varying heparin dosages.

Main Results:

• Abciximab significantly reduced the incidence of postprocedural ischaemic events in all three trials.
• A dose-related effect was observed in the EPIC trial, with a 35% reduction in composite endpoint.
• EPILOG showed a 56% reduction in composite endpoint with abciximab and low-dose heparin; CAPTURE showed a 29% reduction.
• Treatment benefits were maintained throughout a 6-month follow-up period.

Conclusions:

• Platelet GP IIb/IIIa receptor inhibition with abciximab markedly reduces ischaemic complications following coronary intervention.
• While bleeding risk exists, it can be managed through optimized adjunctive therapy and vascular access management.
• Further research is exploring GP IIb/IIIa inhibitors in acute coronary syndromes and with new revascularization devices.